Janssen Vaccines & Prevention B.v.

Remko Van Der Vlugt

Taco Gilles Uil

Jort Vellinga

Kerstin Wunderlich

Barbara Petronella Sanders

Miriam Verena Bujny

Donata De Marco

The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.

Potent and short promoter for expression of heterologous genes

The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of specifically binding to and neutralizing at least one influenza B virus strain from the B/Victoria lineage and/or at least one influenza B virus strain from the B/Yamagata lineage, as well as antigen-binding fragment thereof. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.

Human neutralizing antibodies binding to influenza B neuraminidase

The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of neutralizing at least one influenza A virus strain comprising NA of the N1 subtype, and antigen-binding fragments thereof. In certain embodiments, the antibodies or antigen-binding fragments furthermore are capable of neutralizing at least one influenza A virus strain comprising NA of the N2 subtype. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.

Growing community of inventors

Zoetermeer, Netherlands

Remko Van Der Vlugt